Mirum Pharmaceuticals, Inc. Contracts & Agreements
63 Contracts & Agreements
- Business Finance (21 contracts)
- Business Operations (2)
- Human Resources (17)
- Intellectual Property (7)
- Real Estate (4)
- Uncategorized (12)
- Mirum Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (Filed With SEC on August 7, 2024)
- Offer Letter by and between the Registrant and Joanne Quan, dated January 11, 2024 (Filed With SEC on May 8, 2024)
- Forms of restricted stock unit grant notice and award agreement for non-employee directors electing to defer settlement of restructured stock units under the Mirum... (Filed With SEC on May 8, 2024)
- Mirum Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (Filed With SEC on May 8, 2024)
- Third Amendment to Office Lease, dated January 17, 2024, by and between the Registrant and Hudson Metro Center, LLC (Filed With SEC on March 15, 2024)
- Mirum Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (Filed With SEC on March 15, 2024)
- Office Lease, dated January 17, 2024, by and between the Registrant and Hudson Metro Center, LLC (Filed With SEC on March 15, 2024)
- Mirum Pharmaceuticals, Inc. 2020 Inducement plan, as amended August 24, 2023 (Filed With SEC on March 15, 2024)
- Description of Common Stock of the Registrant (Filed With SEC on March 15, 2024)
- Sales Agreement by and between the Registrant, Leerink Partners LLC and Cantor Fitzgerald & Co., dated November 2, 2023 (Filed With SEC on November 2, 2023)
- Offer Letter by and between the Company and Eric Bjerkholt, dated August 8, 2023 (Filed With SEC on September 11, 2023)
- Mirum Pharmaceuticals, Inc. Amended and Restated Severance Benefit Plan and form of Participation Agreement thereunder (Filed With SEC on August 30, 2023)
- Form of Subscription Agreement (Filed With SEC on August 7, 2023)
- Asset Purchase Agreement, dated July 16, 2023, by and between Mirum Pharmaceuticals, Inc. and Travere Therapeutics, Inc (Filed With SEC on July 17, 2023)
- Form of Subscription Agreement (Filed With SEC on July 17, 2023)
- Form of Registration Rights Agreement (Filed With SEC on July 17, 2023)
- Indenture, dated as of April 17, 2023, between Mirum Pharmaceuticals, Inc. and U.S. Bank Trust Company, National Association, as trustee (Filed With SEC on April 17, 2023)
- Transition, Separation and Consulting Agreement, dated January 7, 2023, by and between the Registrant and Ian Clements, Ph.D (Filed With SEC on January 9, 2023)
- Underwriting Agreement by and among the Company, J.P. Morgan Securities LLC, SVB Securities LLC and Evercore Group L.L.C., dated August 9, 2022 (Filed With SEC on August 10, 2022)
- Mirum Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended March 18, 2020 (Filed With SEC on March 9, 2022)
- Forms of international restricted stock unit grant notice and award agreement under the Mirum Pharmaceuticals, Inc. 2020 Inducement Plan (Filed With SEC on March 9, 2022)
- Forms of international grant notice, stock option agreement and notice of exercise under the Mirum Pharmaceuticals, Inc. 2020 Inducement Plan (Filed With SEC on March 9, 2022)
- Mirum Pharmaceuticals, Inc. 2019 Employee Stock Purchase Plan Terms and conditions Non-U.S. Participants (Filed With SEC on March 9, 2022)
- Forms of international restricted stock unit grant notice and award agreement under the Mirum Pharmaceuticals, Inc. 2019 Equity Incentive Plan (Filed With SEC on March 9, 2022)
- Forms of international director grant notice, stock option agreement and notice of exercise under the Mirum Pharmaceuticals, Inc. 2019 Equity Incentive Plan (Filed With SEC on March 9, 2022)
- Forms of international grant notice, stock option agreement and notice of exercise under the Mirum Pharmaceuticals, Inc. 2019 Equity Incentive Plan (Filed With SEC on March 9, 2022)
- Asset Purchase Agreement, dated November 16, 2021, by and between the Registrant and Janssen Biotech, Inc (Filed With SEC on November 19, 2021)
- Amendment No. 1 to Revenue Interest Purchase Agreement, dated September 28, 2021 (Filed With SEC on September 29, 2021)
- Offer Letter by and between the Registrant and Peter Radovich, dated April 28, 2020 (Filed With SEC on March 9, 2021)
- Underwriting Agreement by and among the Company, J.P. Morgan Securities LLC, SVB Leerink LLC and Evercore Group L.L.C., dated December 14, 2020 (Filed With SEC on December 15, 2020)
- Forms of restricted stock unit grant notice and award agreement under the Mirum Pharmaceuticals, Inc. 2020 Inducement Plan (Filed With SEC on May 7, 2020)
- Forms of grant notice, stock option agreement and notice of exercise under the Mirum Pharmaceuticals, Inc. 2020 Inducement Plan (Filed With SEC on May 7, 2020)
- Mirum Pharmaceuticals, Inc. 2020 Inducement Plan (Filed With SEC on May 7, 2020)
- Description of Common Stock of the Registrant (Filed With SEC on March 12, 2020)
- Office Lease by and between the Registrant and Hudson Metro Center, LLC, dated January 22, 2019, as amended by First Amendment by and between the Registrant and Hudson Metro... (Filed With SEC on January 6, 2020)
- Form of Underwriting Agreement (Filed With SEC on January 6, 2020)
- Amended and Restated Offer Letter by and between the Company and Michael Grey, dated May 15, 2019, as amended by the Letter Agreement by and between the Company and Michael Grey,... (Filed With SEC on December 27, 2019)
- Offer Letter by and between the Registrant and Edwin J. Tucker, MD, dated October 21, 2019 (Filed With SEC on November 6, 2019)
- Form of Underwriting Agreement (Filed With SEC on July 8, 2019)
- Form of Common Stock Certificate (Filed With SEC on July 8, 2019)
- Mirum Pharmaceuticals, Inc. 2019 Equity Incentive Plan, to be in effect when this registration statement is declared effective (Filed With SEC on July 8, 2019)
- Forms of grant notice, stock option agreement and notice of exercise under the Mirum Pharmaceuticals, Inc. 2019 Equity Incentive Plan, to be in effect when this registration... (Filed With SEC on July 8, 2019)
- Forms of restricted stock unit grant notice and award agreement under the Mirum Pharmaceuticals, Inc. 2019 Equity Incentive Plan, to be in effect when this registration statement... (Filed With SEC on July 8, 2019)
- Form of Indemnification Agreement by and between the Registrant and each director and executive officer (Filed With SEC on July 8, 2019)
- Mirum Pharmaceuticals, Inc. 2019 Employee Stock Purchase Plan (Filed With SEC on July 8, 2019)
- License Agreement by and between Lumena Pharmaceuticals, Inc. and Sanofi-Aventis Deutschland GmbH, dated September 27, 2012 (Filed With SEC on July 8, 2019)
- Mirum Pharmaceuticals, Inc. 2018 Equity Incentive Plan (Filed With SEC on June 21, 2019)
- Forms of grant notice, stock option agreement and notice of exercise under the Mirum Pharmaceuticals, Inc. 2018 Equity Incentive Plan (Filed With SEC on June 21, 2019)
- Mirum Pharmaceuticals, Inc. Severance Benefit Plan and form of Participation Agreement thereunder (Filed With SEC on June 21, 2019)
- Amended and Restated Offer Letter by and between the Registrant and Michael Grey, dated May 15, 2019 (Filed With SEC on June 21, 2019)
- Amended and Restated Offer Letter by and between the Registrant and Christopher Peetz, dated May 15, 2019 (Filed With SEC on June 21, 2019)
- Offer Letter by and between the Registrant and Pamela Vig, Ph.D., dated December 1, 2018 (Filed With SEC on June 21, 2019)
- Offer Letter by and between the Registrant and Lara Longpre, dated December 1, 2018 (Filed With SEC on June 21, 2019)
- Offer Letter by and between the Registrant and Ian Clements, Ph.D., dated March 4, 2019 (Filed With SEC on June 21, 2019)
- Office Lease by and between the Registrant and Hudson Metro Center, LLC, dated January 22, 2019 (Filed With SEC on June 21, 2019)
- License Agreement by and between Lumena Pharmaceuticals, Inc. and Satiogen Pharmaceuticals, Inc., dated February 8, 2011 (Filed With SEC on June 21, 2019)
- Amendment to License Agreement by and between Lumena Pharmaceuticals, Inc. and Satiogen Pharmaceuticals, Inc., dated February 28, 2011 (Filed With SEC on June 21, 2019)
- License Agreement by and between Lumena Pharmaceuticals, Inc. and Pfizer Inc., dated June 1, 2012 (Filed With SEC on June 21, 2019)
- Amendment No. 1 to License Agreement by and between Shire Orphan and Rare Disease GmbH (successor in interest of Lumena Pharmaceuticals, Inc.) and Sanofi-Aventis Deutschland GmbH,... (Filed With SEC on June 21, 2019)
- Assignment and License Agreement by and between the Registrant and Shire International GmbH, dated November 5, 2018 (Filed With SEC on June 21, 2019)
- Transition Services Agreement by and between the Registrant and Shire International GmbH, dated January 28, 2019 (Filed With SEC on June 21, 2019)
- Investors Rights Agreement, dated November 5, 2018 (Filed With SEC on June 21, 2019)
- License Agreement by and between Lumena Pharmaceuticals, Inc. and Sanofi-Aventis Deutschland GmbH, dated September 27, 2012 (Filed With SEC on June 21, 2019)
